MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Change in Cash
$66,460K
Free Cash flow
$1,518K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Redemption of term deposits
    • Decrease in r&d benefit receivab...
    • Decrease in trade and other paya...
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • (increase)/decrease in other cur...
    • Other income, net
    • Decrease in operating lease liab...
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-12,268
-14,957
-11,770
-76,842
Depreciation expense
73
72
77
235
Amortization expense
35
34
36
207
Share-based compensation expense
1,308
2,447
-86
8,160
Net foreign exchange impacts
-178
25
-230
-10,792
Other income, net
584
519
880
2,600
Income tax expense
1
-
0
11
Decrease in trade receivables
0
0
-30
-994
(increase)/decrease in other current assets
2,329
-931
1,741
-7,757
Decrease in r&d benefit receivable
-12,924
209
-190
-3,851
Decrease in other long-term assets
0
0
-257
-3,401
Decrease in trade and other payables
2,204
-2,949
-3,576
-502
Decrease in contract liabilities
0
-404
-32
-302
Decrease in operating lease liabilities
-24
-24
-22
-146
Net cash used in operations
1,518
-15,603
-17,287
-44,984
Redemption of term deposits
64,940
74,427
20,440
98,036
Purchase of term deposits
0
64,427
73,778
92,635
Purchase of property, plant and equipment
0
0
0
55
Net cash provided by/(used in) investing activities
64,940
10,000
-53,338
5,346
Proceeds from issue of ordinary shares
2
0
0
15
Net cash provided by financing activities
2
0
0
15
Increase/(decrease) in cash and cash equivalents
66,460
-5,603
-70,625
-39,623
Cash and cash equivalents at start of period
5,657
11,277
82,031
121,330
Effect of exchange rate fluctuations on cash and cash equivalents held
-63
-17
-129
324
Cash and cash equivalents, end of period
72,054
5,657
11,277
82,031
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Redemption of term deposits$64,940K Decrease in r&d benefitreceivable-$12,924K Proceeds from issue ofordinary shares$2K Decrease in trade andother payables$2,204K Share-based compensationexpense$1,308K Net foreignexchange impacts-$178K Depreciation expense$73K Amortization expense$35K Income tax expense$1K Net cash providedby/(used in) investing...$64,940K Net cash used inoperations$1,518K Net cash provided byfinancing activities$2K Canceled cashflow$15,205K Increase/(decrease) in cash and cashequivalents$66,460K Net loss-$12,268K (increase)/decrease in other currentassets$2,329K Other income, net$584K Decrease in operatinglease liabilities-$24K

Silence Therapeutics plc (SLNCF)

Silence Therapeutics plc (SLNCF)